NCT06105983View on ClinicalTrials.gov

A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions
Healthy
Interventions
DRUG

Sisunatovir

Single Dose

DRUG

Rabeprazole 40 mg

Tablets once daily for 7 days

DRUG

Sisunatovir suspension

Tablets once daily for 7 days

DRUG

Rabeprazole 20 mg

Tablets once daily for 7 days

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06105983 - A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. | Biotech Hunter | Biotech Hunter